益盛药业(002566) - 2015 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2015 was ¥180,622,801.01, representing a 5.13% increase compared to ¥171,807,372.44 in the same period last year[8] - Net profit attributable to shareholders decreased by 18.08% to ¥14,088,851.14 from ¥17,198,580.59 year-on-year[8] - The net profit after deducting non-recurring gains and losses fell by 32.10% to ¥9,558,258.93 compared to ¥14,077,353.21 in the previous year[8] - Basic and diluted earnings per share both decreased by 20.00% to ¥0.04 from ¥0.05 year-on-year[8] - The weighted average return on equity decreased by 0.22% to 0.81% from 1.03% year-on-year[8] - The net profit attributable to shareholders for the first half of 2015 is expected to be between 6,346.75 and 7,323.17 million RMB, representing a growth of 30.00% to 50.00% compared to 4,882.11 million RMB in the same period of 2014[24] Cash Flow and Assets - The net cash flow from operating activities was negative at -¥324,392,201.22, worsening by 177.98% from -¥116,694,418.06 in the same period last year[8] - Total assets increased by 9.39% to ¥2,724,239,729.85 from ¥2,490,347,063.26 at the end of the previous year[8] - Net assets attributable to shareholders rose by 0.81% to ¥1,744,583,187.58 compared to ¥1,730,494,336.44 at the end of the previous year[8] - The company's cash and cash equivalents decreased by 14.83% to ¥265,826,361.90 due to increased procurement of red ginseng and sun-dried ginseng[17] - Accounts receivable increased by 28.49% to ¥218,264,241.33, attributed to a decrease in sales collections during the reporting period[17] - Prepayments surged by 141.19% to ¥174,067,748.73, primarily due to increased advance payments for red ginseng procurement[17] Expenses and Investments - Financial expenses skyrocketed by 383.59% to ¥7,003,033.67, resulting from higher interest expenses due to increased short-term borrowings[18] - Investment income plummeted by 78.99% to ¥315,616.43, reflecting reduced returns from financial product investments[18] - Cash paid for purchasing goods and services increased by 59.21% to ¥370,000,211.86, due to higher procurement of red ginseng and related products[19] - Cash received from investment decreased by 61.30% to ¥80,000,000.00, attributed to fewer matured financial products being redeemed[20] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 22,502[12] - The largest shareholder, Zhang Yisheng, holds 38.88% of the shares, totaling 128,677,572 shares[12] Future Outlook and Strategy - The company plans to maintain a stable dividend policy, ensuring cash dividends are not less than 10% of the annual distributable profit[22] - The company has committed to not engage in high-risk securities investments for twelve months after repaying bank loans and supplementing working capital[23] - The company continues to increase marketing efforts in the pharmaceutical sector, contributing to stable revenue growth[25] - The sales of ginseng-related products are expected to positively impact the company's performance as they gradually enter the market[25]